Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 5.51%.

  • Harvard Bioscience's EBT Margin rose 149300.0% to 5.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.34%, marking a year-over-year decrease of 476700.0%. This contributed to the annual value of 12.39% for FY2024, which is 101100.0% down from last year.
  • Harvard Bioscience's EBT Margin amounted to 5.51% in Q3 2025, which was up 149300.0% from 11.02% recorded in Q2 2025.
  • Harvard Bioscience's 5-year EBT Margin high stood at 11.71% for Q2 2022, and its period low was 233.28% during Q1 2025.
  • In the last 5 years, Harvard Bioscience's EBT Margin had a median value of 3.92% in 2023 and averaged 18.11%.
  • As far as peak fluctuations go, Harvard Bioscience's EBT Margin soared by 284100bps in 2023, and later tumbled by -2149900bps in 2025.
  • Over the past 5 years, Harvard Bioscience's EBT Margin (Quarter) stood at 3.42% in 2021, then crashed by -192bps to 3.14% in 2022, then decreased by -25bps to 3.92% in 2023, then surged by 161bps to 2.4% in 2024, then crashed by -329bps to 5.51% in 2025.
  • Its EBT Margin stands at 5.51% for Q3 2025, versus 11.02% for Q2 2025 and 233.28% for Q1 2025.